IMR Press / FBL / Volume 10 / Issue 2 / DOI: 10.2741/1682

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Article
HIV vaccine development
Show Less
1 Molecular Virology Section, Laboratory of Molecular Medicine, NIAID, NIH, Bethesda, Maryland, USA
2 Saint Michael’s Medical Center, Newark, New Jersey, USA
3 New Jersey Medical School, Newark, New Jersey, USA
Front. Biosci. (Landmark Ed) 2005, 10(2), 2064–2081; https://doi.org/10.2741/1682
Published: 1 September 2005
Abstract

For the past two decades, scientists have aggressively pursued the development of a vaccine against human immunodeficiency virus (HIV). The magnitude of this effort is unprecedented in the history of infectious diseases. However, difficulties in finding promising candidate vaccines have limited the number of clinical efficacy trials. The macaque model is well suited for the evaluation of potential vaccines, but comparison of results among studies is often complicated by the use of different macaque species and/or challenge viruses. This review discusses current results obtained in the macaque model and human vaccine trials.

Keywords
HIV-1
HIV-2
SIV
SIVmne
SIVmac
SHIV
Macaque
Human Vaccine Trials
Prime-Boost
Inactivated Whole Virus
Live-Attenuated
Passive Immunization
Mechanism of Protection
Review
Share
Back to top